EFPIA Names Joe Jimenez as New President
EFPIA announced that Joe Jimenez, CEO of Novartis, has been appointed as its new president, following confirmation by the EFPIA Board on December 9. Jimenez will work alongside Dr. Stefan Oschmann, CEO Pharma of Merck KGaA, and Marc de Garidel, Chairman and CEO of Ipsen, who have been appointed as vice-presidents by the Board, also on December 9.
Jimenez previously served as EFPIA vice-president. He was already EFPIA’s president-elect at the time of former EFPIA president Chris Viehbacher’s resignation on October 29, 2014 and due to take over leadership of EFPIA in June 2015. The Board has agreed to extend Joe Jimenez’s appointment until June 2017; this is to be ratified during the EFPIA General Assembly in June 2015.
Source: EFPIA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
